Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose levosimendan for sepsis-induced myocardial dysfunction
ChiCTR2500101261Phase 4Completed
- Sponsor
- Affiliated Hospital of Hangzhou Normal University
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of levosimendan in myocardial dysfunction and sepsis (2 arms), sponsored by Affiliated Hospital of Hangzhou Normal University. Primary endpoints: 28-day mortality rate and Mean arterial pressure. Started Dec 2022; status: completed.
02
Drugs
levosimendan
03
Conditions
myocardial dysfunctionsepsis
Beyond the preview
Go deeper on ChiCTR2500101261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101261.